MAPT and Alzheimer disease: The revised Alzheimer's Association criteria for the diagnosis and staging of AD [5] categorize tau biomarkers into two groups: T1 biomarkers, which reflect early tau hyperphosphorylation associated with Aβ pathology, and T2 biomarkers, which indicate later-stage tau aggregation and neurofibrillary tangle formation.